The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells
出版年份 2022 全文链接
标题
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells
作者
关键词
-
出版物
BIOCHEMICAL PHARMACOLOGY
Volume 205, Issue -, Pages 115294
出版商
Elsevier BV
发表日期
2022-10-12
DOI
10.1016/j.bcp.2022.115294
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
- (2022) Aaron C. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy
- (2022) Anubhab Mukherjee et al. ACTA PHARMACOLOGICA SINICA
- Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers
- (2022) Chao-Yu Liu et al. Journal of the Chinese Medical Association
- Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
- (2021) Hidetoshi Hayashi et al. Clinical Lung Cancer
- Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
- (2021) Liping Hu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Liposomes: Advancements and innovation in the manufacturing process
- (2020) Sanket Shah et al. ADVANCED DRUG DELIVERY REVIEWS
- Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
- (2020) Zhen Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness
- (2019) Michela Terlizzi et al. PHARMACOLOGY & THERAPEUTICS
- Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
- (2019) Nele Van Der Steen et al. BIOCHEMICAL PHARMACOLOGY
- Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer
- (2019) Priyanka Chowdhury et al. BMC CANCER
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer
- (2018) Najwa El Kadi et al. CANCER RESEARCH
- Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways
- (2017) Zhen Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Crizotinib resistance: implications for therapeutic strategies
- (2016) I. Dagogo-Jack et al. ANNALS OF ONCOLOGY
- Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
- (2016) Masayoshi Miyawaki et al. MOLECULAR CANCER RESEARCH
- Activation of EGFR Bypass Signaling by TGF Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
- (2015) T. Tani et al. MOLECULAR CANCER THERAPEUTICS
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now